🇺🇸 FDA

Intelligence Platform

Patents

Browse 92 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11401346

Nucleic acids encoding plasma kallikrein binding proteins

Takeda Pharmaceutical Company Limited · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390687

Bispecific antibodies against plasma kallikrein and Factor XII

Takeda Pharmaceutical Company Limited · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11372002

Assays for determining plasma kallikrein system biomarkers

Takeda Pharmaceutical Company Limited · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370803

Heteroaryl plasma kallikrein inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352356

Inhibitors of plasma kallikrein and uses thereof

Takeda Pharmaceutical Company Limited · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299553

Anti-plasma kallikrein antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11286307

Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Takeda Pharmaceutical Company Limited · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11242333

Inhibitors of plasma kallikrein

KalVista Pharmaceuticals Limited · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11234939

Dosage forms comprising a plasma kallikrein inhibitor

KalVista Pharmaceuticals Limited · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11230537

Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyr

KalVista Pharmaceuticals Limited · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11230530

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11203574

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11198691

N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

KalVista Pharmaceuticals Limited · Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11192861

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11180484

Pyrazole derivatives as plasma kallikrein inhibitors

KalVista Pharmaceuticals Limited · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11168083

Inhibitors of Plasma Kallikrein and uses thereof

Takeda Pharmaceutical Company Limited · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117867

Crystalline salts of a plasma kallikrein inhibitor

BioCryst Pharmaceuticals, Inc. · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11084884

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Takeda Pharmaceutical Company Limited · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11084809

N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

KalVista Pharmaceuticals Limited · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066360

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11033623

Magnetic stem cell therapy for lesions

GREINER BIO-ONE NORTH AMERICA, INC. · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11001578

N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

KalVista Pharmaceuticals Limited · Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934544

Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and k

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10894808

Polypeptide ligands specific for plasma kallikrein

BicycleRD Limited · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted